Executive Summary
Copart operates one of the most compelling near-toll-booth franchises in industrial services — a duopoly (with IAA/RB Global) in salvage vehicle auctions that insurance companies cannot economically bypass. When an insurer declares a vehicle a total loss, the salvage process must flow through an auction platform with the buyer network, land infrastructure, and technology to maximize recovery values. Using split-adjusted EPS from ROIC.ai — $0.99 (FY21), $1.15 (FY22), $1.30 (FY23), $1.42 (FY24) — and normalizing at approximately $1.29 mid-cycle, the stock trades at roughly 26x normalized earnings. This is not cheap for a business currently reporting a -3.6% revenue decline and -8% unit volumes, but it is reasonable for a franchise with 35-40% operating margins and durable competitive positioning. The majority views the current unit decline as cyclical rather than structural, driven by consumer pullback on collision coverage, softer claims activity, and elevated repair-vs-total thresholds — all forces that have historically mean-reverted with insurance pricing cycles. However, the timing and pace of recovery remain uncertain, and leading indicators like policies-in-force and collision coverage attachment rates have not yet inflected. With the stock trading near our estimated fair value of $35-38 per share, we see no urgency to establish positions today. We would prefer to accumulate shares at $29-31, which provides a 15-20% margin of safety and better compensates for near-term earnings uncertainty. Capital allocation is adequate but not exceptional at this stage. Management has repurchased approximately $500M in shares year-to-date (~15 million shares at ~$33), representing roughly 1.5% of shares outstanding. However, the share count rose from 933 million in FY20 to 961 million in FY24, indicating that stock-based compensation has historically offset buybacks. Net accretion may be closer to 0.5-1.0% annually once SBC dilution is netted — meaningful over time but not a primary return driver. The company's strong balance sheet (approximately $2.0-2.5 billion in net cash after reconciling balance sheet figures) provides both downside protection and optionality for opportunistic capital deployment. On a blended valuation — averaging P/E ($1.29 × 27x = $34.83), FCF yield ($0.99 FCF/share at a 2.8% yield = $35.36), and EV/EBIT (~$1.6B operating income at 22x less net cash = $34.33) — fair value centers around $35-37 per share, with upside to $38-40 if unit volumes recover to trend growth within 18 months. At $33.39, the risk/reward is modestly favorable but does not offer the margin of safety we require for a full position. We recommend beginning to accumulate below $30 and building conviction as insurance volume data inflects.
The minority sees Copart at $33.39 as a compelling asymmetric opportunity in a dominant franchise experiencing temporary cyclical headwinds. Insurance volume cycles have always mean-reverted — the question is timing, not direction. With the stock trading at roughly 23x TTM earnings of $1.42 for a business with 35-40% operating margins, a near-monopoly position in salvage auctions, and ~$2B in net cash, the downside is well-protected while the upside from volume normalization could drive 20-30% returns within 18 months. Waiting for $29-30 risks missing the recovery entirely, as insurance volume data tends to inflect quickly once carrier pricing cycles complete. David Tepper sees classic catalyst-driven asymmetry: downside to ~$27-28 (a further 15-17% decline requiring sustained volume deterioration and multiple compression) versus upside to $40-42 (volume recovery driving EPS to $1.55+ at 26-27x). That's roughly 2:1 reward-to-risk, which is actionable. Mohnish Pabrai frames it as a quintessential 'heads I win, tails I don't lose much' situation — the company's land portfolio alone (which Copart owns rather than leases) provides a significant asset floor, while the duopoly market structure ensures Copart will participate fully in any volume recovery. Both minority members acknowledge the SBC dilution concern and the uncertainty around volume recovery timing, but argue that these are well-understood risks already reflected in the multiple compression from historical averages of 30-35x to the current 23-26x range. The market is giving you a quality compounder at a cyclical trough multiple — that's precisely when patient capital should be deployed.